Overview
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.
Participants undergo the following process:
There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject.
These are processed into human cells for administration and injected into the subject.
Description
Administer a fixed dose of CHA-TIL to the subject as a single intravenous infusion and evaluate safety and preliminary efficacy for 6 months.
Eligibility
Inclusion Criteria:
- Recurrent ovarian cancer
- There is a cancerous lesion that can be removed by biopsy or surgery.
Exclusion Criteria:
- Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
- Patient deemed unsuitable by the principal investigator
